Loading clinical trials...

Treatment of Apathy in Alzheimer's Disease With Modafinil | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Treatment of Apathy in Alzheimer's Disease With Modafinil

NCT01172145•Brown University

Summary

This study examined the effects of modafinil on apathetic symptomatology, performance of activities of daily living (ADLs) and caregiver burden in individuals with Alzheimer's disease (AD).

Eligibility

Age

65 - 95 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•diagnosis of mild to moderate stage Probable Alzheimer's disease
•on a stable dose of a cholinesterase inhibitor medication for at least 30 days
•clinically elevated levels of apathy as measured by the Frontal Systems Behavior Scale

Exclusion Criteria

•diagnosis of Major Depression
•focal brain lesion on neuroimaging
•history of significant substance abuse
•history of significant head trauma with loss if consciousness \>10 minutes

Locations (1)

Butler Hospital

Providence, Rhode Island, United States

Key Dates

Start Date

July 1, 2005

Completion Date

September 1, 2007

Last Updated

March 4, 2011

Enrollment

ACTUAL participants

Conditions

ApathyAlzheimer's Disease

Interventions

Modafinil

DRUG

Placebo

DRUG

ACP-204 in Adults With Alzheimer's Disease Psychosis

NCT06159673

Alzheimer's Disease Psychosis

View study

RECRUITING

Lombard Cohort of Brain Health Services

NCT07457138

Subjective Cognitive Decline (SCD)Functional Cognitive Disorder+2 more

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 4, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Treatment of Apathy in Alzheimer's Disease With Modafinil

Inclusion Criteria

Exclusion Criteria

ACP-204 in Adults With Alzheimer's Disease Psychosis

Lombard Cohort of Brain Health Services

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia